MAP3K14 and liver disorder: Our results unveil biliary NIK as a previously-unrecognized molecular driver for ductular reaction, liver injury, inflammation, and fibrosis, and raise the possibility that NIK inhibitors may have therapeutic potential for liver disease treatment.